Browse the evidence

Average weight loss was 1.3kg (SD 2.3, P=0.03).

Weight loss can be achieved through mindful eating interventions using technology.

Participants on the healthy vegan diet lost more body weight after 8 weeks compared to those on the healthy omnivorous diet (-1.9 vs. -0.29 kg).

Adopting a vegan diet may facilitate greater weight loss compared to an omnivorous diet.

The iDiet prioritizes hunger suppression more than other conventional behavioral programs.

Practitioners should consider the iDiet's emphasis on hunger suppression when advising clients.

Higher adherence to whole food plant-based (WFPB) and vegan diets is significantly associated with lower BMI.

Encouraging adherence to WFPB and vegan diets may help individuals achieve lower body weight.

Fully plant-based diets (WFPB and vegan) have the healthiest Healthy Eating Index (HEI) scores and BMIs.

Promoting fully plant-based diets may lead to improved diet quality and health outcomes.

Pharmacotherapy is an important adjunct to lifestyle and behavioral modifications in obesity management.

Practitioners should consider pharmacotherapy for patients struggling with weight loss despite lifestyle changes.

The study cohort lost an average of 23% of their BMI from baseline.

Weight loss programs can lead to significant reductions in BMI among employees.

The treatment of obesity includes lifestyle modifications, pharmacological interventions, and surgical procedures.

Practitioners should implement a multifaceted approach to obesity treatment.

The main objective of obesity pharmacotherapy is weight loss and weight loss maintenance.

Weight loss medications should be viewed as tools for achieving and maintaining weight loss.

The position statement includes recommendations on the overall management of obesity.

Healthcare providers should utilize these recommendations to improve obesity management.

The treatment of obesity requires a multifaceted approach, including lifestyle interventions, pharmacological treatments, and bariatric surgery.

Practitioners should implement a combination of lifestyle changes, medications, and consider surgical options for effective obesity treatment.

Body weight decreased by 13.3% in patients treated with semaglutide compared to a marginal decrease of -2.6% in placebo-treated patients (P < .001).

Semaglutide can significantly aid in weight loss for obese patients with heart failure.

AOM use prior to BMS is associated with significantly higher weight loss until the day of surgery (1.37 vs. 0.05; p = 0.04).

Practitioners may consider AOMs as a beneficial preoperative strategy for weight loss in bariatric surgery candidates.

Lifestyle therapies, including weight loss and diet, are effective for managing obesity-related hypertension.

Encouraging weight loss and dietary changes can be beneficial for patients with obesity-related hypertension.

New dietary interventions are poised to overtake traditional strategies as the ideal approach to achieving sustained weight loss for obesity-associated hypertension patients.

Practitioners should consider implementing new dietary interventions for better weight loss outcomes in patients.

Obesity has been associated with an increased risk of all-cause and cardiovascular mortality.

Awareness of the mortality risks associated with obesity is essential for patient management.

Lessened emotional eating is significantly associated with concurrent reductions in weight and waist circumference.

Reducing emotional eating can be an effective strategy for achieving weight loss and waist circumference reduction.

Median time to maintenance was significantly shorter for Tirzepatide (32 days) than Semaglutide (143 days).

Practitioners may prefer Tirzepatide for quicker dose optimization.

Obesity medications (OMs) produce meaningful weight loss (∼5%-24%) and improve cardiometabolic health.

Practitioners can expect significant weight loss and health benefits from OMs.

Weight loss of at least 10% is required to achieve meaningful clinical remission rates in NASH.

Weight management strategies should aim for at least a 10% reduction in body weight for patients with NASH.

At 15 months, total body weight loss (TBWL) was greater in mild versus severe IMS groups (14.8% vs. 11.0%, p = 0.015).

Clinicians should consider IMS severity when predicting weight loss outcomes with tirzepatide.

The proportion achieving ≥ 20% TBWL was nearly two-fold higher in mild versus severe IMS (27% vs. 14%, p = 0.03).

Higher IMS severity is associated with lower chances of achieving significant weight loss with tirzepatide.

The nutritional guidance-only group experienced the most pronounced reduction in body mass.

Nutritional guidance alone can lead to significant weight loss in overweight and obese women.

LIGHT 2 is a seamless, adaptive phase 2b/3 trial evaluating the efficacy and safety of efsubaglutide alfa for chronic weight management in adults with overweight or obesity.

This trial aims to provide evidence on the effectiveness of efsubaglutide alfa for weight management.